Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal recessive lysosomal disease caused by biallelic loss of function variants in the SMPD1 gene. Clinical symptoms in affected individuals occur along a continuum. At the severe end of the spectrum are individuals historically diagnosed with Niemann-Pick disease type A (the neurovisceral form), which is characterized by hepatosplenomegaly with rapid neurological deterioration leading to death in the first few years of life. At the milder end of the spectrum are individuals historically diagnosed with Niemann-Pick disease type B, a later-onset, chronic visceral form, characterized by progressive visceral organ symptoms including hepatosplenomegaly and pulmonary insufficiency, and survival into adulthood. In addition, some affected individuals present with an intermediate phenotype, Niemann-Pick disease type A/B.
No HPO annotations are available for this condition.
Age of onset: infancy.
Although the phenotype of acid sphingomyelinase deficiency (ASMD) occurs along a continuum, individuals with the severe early-onset infantile neurovisceral phenotype (Niemann-Pick disease type A, or NPD-A) can often be distinguished from those with the intermediate chronic neurovisceral phenotype (NPD-A/B) and chronic visceral ASMD (Niemann-Pick disease type B, or NPD-B) based on clinical presentation. Enzyme replacement therapy (ERT) is currently FDA approved for the non-central nervous system manifestations of ASMD, regardless of type (see Management, ). As more affected individuals are treated with ERT for longer periods of time, the natural history of ASMD is likely to change.
Acid sphingomyelinase deficiency (ASMD) cannot be diagnosed solely on clinical grounds.
Suggestive Findings
NBS for ASMD is primarily based on quantification of acid sphingomyelinase activity on dried blood spots. At the time of writing, ASMD is not included on the United States Recommended Uniform Screening Panel and is performed in a limited number of states within the US. Several pilot studies have also been performed in Europe. Acid sphingomyelinase activity values below the cutoff reported by the screening laboratory are considered positive and require follow-up biochemical and/or molecular genetic testing for confirmation.
1 FDA-approved treatment is available for acid sphingomyelinase deficiency, including OLIPUDASE ALFA-RPCP (XENPOZYME, approved 2022).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Recommendations for clinical monitoring of individuals with ASMD have been published . These were published prior to the availability of ERT. However, such evaluations should still be considered, even for those on ERT, to assess for the individual's response to targeted and supportive care and the emergence of new manifestations. Table 6. Recommended Surveillance for Individuals with Acid Sphingomyelinase Deficiency
5 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05368038](https://clinicaltrials.gov/study/NCT05368038) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:30 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Common questions about acid sphingomyelinase deficiency
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
Lysosomal storage diseases (LSD). The clinical features of acid sphingomyelinase deficiency (ASMD) may overlap with other lysosomal storage diseases such as Gaucher disease; however, biochemical and/or molecular genetic testing permits clear distinction between these disorders. Recent studies of individuals with hepatosplenomegaly whose testing for Gaucher disease was normal were subsequently found to have ASMD [Author, personal communication]. Pulmonary infiltration and the low serum concentration of high-density lipoprotein cholesterol are distinctive features that are present very early in individuals with ASMD but not in those with Gaucher disease. Hepatosplenomegaly. Other hereditary disorders associated with hepatosplenomegaly are summarized in . Table 2. Disorders with Hepatosplenomegaly in the Differential Diagnosis of Acid Sphingomyelinase Deficiency
Gene(s) | Differential Diagnosis Disorder | MOI | Distinguishing Features |
|---|---|---|---|
ASAH1 | Farber disease (See ASAH1-Related Disorders.) | AR | Joint nodules hoarseness in Farber disease G6PC |
SLC37A4 | Glycogen storage diseases (e.g., GSD1) | AR | Hypoglycemia in glycogen storage diseases GALNS GNS HGSNAT IDS IDUA NAGLU |
SGSH | Mucopolysaccharidoses (e.g., MPS I, MPS II, MPS III, MPS IVA) | ARXL | Coarse facial features dysostosis multiplex in mucopolysaccharidoses GBA1 (GBA) |
Gaucher disease | AR | Interstitial lung disease in ASMD; more prominent skeletal disease in Gaucher disease GNPTAB GNPTG MCOLN1 | — |
Oligosaccharidoses (e.g., GNPTAB-related disorders, mucolipidosis III gamma, mucolipidosis IV) | AR | Coarse features dermatologic ophthalmologic abnormalities may be present in oligosaccharidoses. | — |
HEXA | Tay-Sachs disease (See HEXA Disorders.) | AR | Hepatosplenomegaly lung disease are not common in Tay-Sachs disease. HEXB |
Sandhoff disease | AR | Hepatosplenomegaly lung disease are not common in Sandhoff disease. | — |
LIPA | Wolman disease (See Lysosomal Acid Lipase [LAL] Deficiency.) | AR | Interstitial lung disease is not common in LAL deficiency; splenomegaly is less pronounced than in ASMD. NPC1 |
NPC2 | Niemann-Pick disease type C (NPD-C) | AR | Specific neurologic findings in NPD-C PRF1 STX11 STXBP2 |
UNC13D | Familial hemophagocytic lymphohistiocytosis (HLH) | AR | Familial HLH may present w/fever inflammation may have involvement of organs not typically affected in ASMD. Hepatosplenomegaly can also accompany some infectious diseases (e.g., Epstein-Barr virus, cytomegalovirus). |
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
Biomarker and diagnostic research for acid sphingomyelinase deficiency has been reported in the published literature.
XENPOZYME
OLIPUDASE ALFA-RPCP |
— |
2022 |
Available |
To establish the extent of disease and needs in an individual diagnosed with acid sphingomyelinase deficiency (ASMD), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
Recommended Evaluations Following Initial Diagnosis in Individuals with Acid Sphingomyelinase Deficiency
System/Concern | Evaluation | Comment
| • Growth assessment
Gastroenterology/ nutrition/ feeding team eval
| In persons w/NPD-A:
Incl eval of aspiration risk nutritional status.
Consider eval for gastrostomy tube placement in those w/dysphagia /or aspiration risk.
In persons w/NPD-B:
Assess nutritional status incl appropriate caloric, calcium, vitamin D intake.
Bone age in children age 18 yrs | • Skeletal age, often delayed, is useful for interpreting DXA scans.
Knowledge about additional potential growth yrs can be reassuring to families concerned about child's stature.
| Serum chemistries incl liver transaminases (ALT, AST), albumin, clotting factors | To evaluate for progression of hepatic dysfunction
Liver elastography or FibroScan® | To evaluate for hepatic fibrosis cirrhosis
Liver biopsy in persons w/evidence of deteriorating liver function may be indicated if noninvasive means to ascertain fibrosis are not available. |
| Radiologic exam w/measurement of liver spleen size |
| Compete blood count | To evaluate for thrombocytopenia, leukopenia, anemia
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
Individuals who have splenomegaly should avoid contact sports.
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
5 trials found
System/Concern |
|---|
Evaluation |
|---|
Frequency |
|---|
Cardiac | EKG | Annually Echocardiogram |
Liver function | Serum chemistries incl liver transaminases (ALT, AST), albumin, clotting factors | At least annually Hematologic |
Hepatosplenomegaly | Radiologic measurements of liver spleen size | At baseline as needed |
Pulmonary | Assess for shortness of breath. | At each visit Pulmonary function testing |
Neurologic | Assess neurologic function frequency of headaches. | At least annually Developmental |
Hyperlipidemia | Fasting lipid profile | At least annually |
Musculoskeletal | Assess for extremity pain. | At each visit Bone density assessment (DXA scan) |
resources | Assess for any change in social, domestic, or school- or work-related activities. | At each visit ALT = alanine aminotransaminase; AST = aspartate aminotransferase; DXA = dual-energy x-ray absorptiometry; OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "Acid Sphingomyelinase Deficiency"
— |
Albert Einstein College of Medicine |
ENROLLING_BY_INVITATION |
[NCT07274826](https://clinicaltrials.gov/study/NCT07274826) | Diagnostic Creteria of Acid Sphingomyelinase Deficiency (ASMD) | — | Sohag University | ACTIVE_NOT_RECRUITING |
[NCT05992532](https://clinicaltrials.gov/study/NCT05992532) | GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma | — | Fundación Española de Hematología y Hemoterapía | RECRUITING |
[NCT06192576](https://clinicaltrials.gov/study/NCT06192576) | A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD) | — | Sanofi | RECRUITING |
[NCT06985212](https://clinicaltrials.gov/study/NCT06985212) | National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children | — | Wladimir MAUHIN, Dr | NOT_YET_RECRUITING |
74 publications have been identified in PubMed for acid sphingomyelinase deficiency. Research spans Review / Meta-Analysis (18%), Case Report / Case Series (18%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 13 | 18% |
Patient case studies | 13 | 18% |
Disease patterns and progression | 12 | 16% |
Testing and diagnosis research | 11 | 15% |
Clinical study results | 8 | 11% |
Laboratory research | 8 | 11% |
New treatment approaches | 6 | 8% |
Other research | 3 | 4% |
Pan YW (2026). [PMID: 42028314](https://pubmed.ncbi.nlm.nih.gov/42028314/). *Mol Genet Metab Rep*. [Epidemiology / Natural History]
Lin HH (2026). [PMID: 41692468](https://pubmed.ncbi.nlm.nih.gov/41692468/). *Molecular genetics & genomic medicine*. [Epidemiology / Natural History]
Sidorina A (2026). [PMID: 41429203](https://pubmed.ncbi.nlm.nih.gov/41429203/). *Journal of lipid research*. [Diagnostic / Biomarker]
Sysoev M (2026). [PMID: 42278593](https://pubmed.ncbi.nlm.nih.gov/42278593/). *Int J Mol Sci*. [Review / Meta-Analysis]
Khoshakhlagh M (2026). [PMID: 41501824](https://pubmed.ncbi.nlm.nih.gov/41501824/). *Orphanet journal of rare diseases*. [Epidemiology / Natural History]
Antonello BB (2026). [PMID: 40974024](https://pubmed.ncbi.nlm.nih.gov/40974024/). *American journal of medical genetics. Part A*. [Basic Science / Preclinical]
Giugliani R (2026). [PMID: 41598527](https://pubmed.ncbi.nlm.nih.gov/41598527/). *Journal of clinical medicine*. [Review / Meta-Analysis]
Liu W (2026). [PMID: 41791926](https://pubmed.ncbi.nlm.nih.gov/41791926/). *Journal of clinical lipidology*. [Case Report / Case Series]
Wuyts WA (2026). [PMID: 41697516](https://pubmed.ncbi.nlm.nih.gov/41697516/). *Advances in therapy*. [Basic Science / Preclinical]
Fiori L (2026). [PMID: 42106996](https://pubmed.ncbi.nlm.nih.gov/42106996/). *Pediatr Allergy Immunol*. [Other]
AI-curated news mentioning acid sphingomyelinase deficiency
Updated Aug 19, 2026
A new study highlights the use of multiplex MSMS measurement of lysosomal enzymes for the incidental diagnosis of acid sphingomyelinase deficiency in patients being evaluated for Gaucher disease. This method could enhance diagnostic accuracy and patient management.
A recent case study highlights the complexities of acid sphingomyelinase deficiency (ASMD) in an asplenic patient, presenting severe interstitial lung disorder. This case underscores the need for further research into the respiratory complications associated with ASMD.
A single-center study in Taiwan reports significant improvements in quality of life and general functions for pediatric patients with acid sphingomyelinase deficiency after treatment with olipudase alfa. This research highlights the potential benefits of this therapy in managing the disease.